Work package 2: PRODUCT

Designing an optimal pharmaceutical product is essential for successful therapy, and several current challenges in the drug development can be solved by identifying the optimal product design strategy. Within our consortium there are expertise within a broad range of different formulations strategies from nanomedicine to standard tablets. To utilize all of this the focus of WP2 is “enabling formulations”.

There are three essential areas where the Nordic POP will aim for providing scientific excellence and new innovative solutions for drug delivery systems:

>> biologicals represent a category of protein/peptide based drugs that have rapidly gained momentum - specifically, this WP will focus on product design strategies aiming for non-invasive administration of large molecules,

>> site specific drug delivery covers more efficient and patient friendly products especially for patients with specific need, e.g., in pediatric and geriatric area – WP2 has a special focus on microbiota, mucoadhesion and nanotechnology,

>> poorly water soluble compounds represent a major challenge in the drug development, which will be addressed by lipid-based and amorphous drug delivery systems.

WP2 is led by Gøril Eide Flaten from UiT The Arctic University of Norway.